Can Dog Cancer Come Back After Treatment?

Yes. For some canine cancers, recurrence is not just possible but expected, and your oncology team plans for it from the first appointment.

That sounds bleak stated flatly, so here is the fuller answer. "Coming back" describes several different situations with very different meanings, the odds vary enormously by cancer type, and recurrence is not the same thing as running out of options. Understanding which situation applies to your dog is what turns a frightening abstraction into something you can actually plan around.

The Words Your Oncologist Is Using

These terms get used interchangeably in conversation, and they should not be.

Remission means the cancer is no longer detectable. It does not mean the cancer is gone. As NC State's oncology service puts it directly, remission does not equal cure (North Carolina State University College of Veterinary Medicine, n.d.). This distinction is the single most important thing on this page.

Cure means the cancer is gone and will not return. In practice this is judged by a long disease-free interval rather than known with certainty. It is achievable for some canine cancers, particularly certain tumors removed completely by surgery.

Local recurrence means the tumor grew back at or near the original site. This usually reflects cancer cells left behind at the surgical margin.

Metastasis means the cancer appeared somewhere new, having traveled through blood or lymph. Often this is not new cancer at all but existing microscopic disease that has finally grown large enough to see.

Relapse generally describes cancer returning after a period of remission, a term used most often with lymphoma.

The difference between local recurrence and metastasis matters because they are usually addressed differently. One is often a surgical or radiation problem. The other is a systemic one.

Why Cancer Comes Back

Treatment removes or kills what can be found. It cannot remove what cannot be detected.

Surgery removes visible tumor plus a margin of surrounding tissue. If cancer cells extend beyond what the surgeon took, those cells stay behind and can regrow. This is why your pathology report comments on margins, and why "incomplete" or "dirty" margins change the conversation.

Chemotherapy kills dividing cells throughout the body, but rarely every last one. Surviving cells can repopulate, and some are resistant to the drug that spared them.

And in certain cancers, microscopic spread has already occurred before you ever knew anything was wrong. This is not a treatment failure. It is the biology of the disease.

How Likely Is It? That Depends Entirely on the Cancer

There is no single recurrence rate for "dog cancer." The four most common cancers behave in four different ways.

Lymphoma: Relapse Is Expected

Lymphoma responds beautifully to chemotherapy and then, in the overwhelming majority of dogs, comes back. For multicentric lymphoma treated with CHOP, NC State cites approximately 95% of dogs relapsing (North Carolina State University College of Veterinary Medicine, n.d.).

That number is not a reason to skip treatment. The point of treating lymphoma is good months, not a cure, and NC State frames continued treatment as appropriate as long as patients continue to feel well (North Carolina State University College of Veterinary Medicine, n.d.).

When relapse happens, treatment continues, but the options depend on when the relapse occurred.

If more than two months passed between finishing CHOP and relapse, CHOP can be restarted, which carries roughly an 80% chance of inducing another complete remission (North Carolina State University College of Veterinary Medicine, n.d.). Duration depends partly on how long the first remission lasted.

If relapse came sooner, or during treatment, dogs are generally moved to a rescue protocol instead. This is the chemotherapy-resistant group, and the 80% figure does not apply to them. Rescue protocol response rates range from roughly 30% to 90% depending on the drug combination, with generally shorter response durations (North Carolina State University College of Veterinary Medicine, n.d.).

The pattern to expect: each remission tends to be shorter than the one before it. NC State describes relapse and resistance as devastating but expected consequences, and notes that treatment options are not mutually exclusive, so dogs may move through several protocols as long as quality of life holds.

Mast Cell Tumors: Margins and Grade Drive the Risk

Mast cell tumors are the cancer where "did you get it all?" matters most, and the honest answer from the literature is that recurrence rates vary considerably between studies.

After complete excision with clean margins, reported recurrence rates range from 0% to 11% in some studies and 19% to 37.5% in others. Part of that spread comes from how studies define recurrence in the first place, for instance as a new mass within 2 cm of a previous incision within a year of surgery. After incomplete excision, one study reported a 63.6% recurrence rate, while most reported substantially lower figures of 12% to 30%. In one series, 23% of 28 dogs with incompletely resected grade II tumors experienced local regrowth (Garrett, 2014).

A note on grading, because two systems are in use. The older Patnaik system sorts tumors into grades I, II, and III. The newer two-tier Kiupel system sorts them into low grade and high grade. Your pathology report may use either or both, and the numbers below are not interchangeable between them.

Most mast cell tumors are designated grade II under the three-tier system, and most of these are cured with surgery (Garrett, 2014). The difficulty is identifying which of those grade II tumors belong to the aggressive subset. Under the two-tier system, one analysis found that high-grade tumors with clean margins still recurred frequently, at 35.9%, with no relationship to how wide the margins were (Garrett, 2014).

Mitotic index has emerged as a more reliable predictor than grade alone, and two research groups proposed different cutoffs. One reported survival exceeding 70 months for a mitotic index of 5 or below versus under 2 months above 5. A second found no disease progression at a mitotic index of 0, a median survival of 18 months for 1 to 7, and 3 months above 7. It was the cutoff of 7 or above that was subsequently adopted for the two-tier system (Garrett, 2014).

That difference matters practically. A dog with a mitotic index of 6 falls in the worrying group under the first cutoff and the 18-month group under the adopted one. If your dog's report includes a mitotic index, ask your oncologist which system and cutoff they are applying.

Soft Tissue Sarcomas: Grade Predicts Recurrence Well

Soft tissue sarcomas are locally invasive and tend to recur locally rather than spread, which makes the surgical margin the central issue.

In a study of marginally excised subcutaneous soft tissue sarcomas, recurrence occurred in 7% of grade 1 tumors (3 of 41), 34% of grade 2 tumors (14 of 41), and 75% of grade 3 tumors (3 of 4). Among 30 completely excised tumors with follow-up, there were zero recurrences regardless of grade. Median time to recurrence was 12 months, with a range of 1 to 25 months (McSporran, 2009).

Two caveats on that grade 3 figure. It represents just 3 tumors out of 4, so the percentage is far less certain than it looks. And high-grade soft tissue sarcomas carry a separate metastatic risk of roughly 41% to 44%, with pulmonary metastasis typically developing between 8 months and a year (Mullin, 2016).

The encouraging half of this: for low and intermediate grade tumors removed completely, the risk of recurrence is extremely low (Mullin, 2016). Complete excision of a low-grade soft tissue sarcoma can genuinely be the end of the story.

Osteosarcoma: It Was Already Elsewhere

Osteosarcoma is the case where "came back" is arguably the wrong phrase.

Approximately 90% to 95% of dogs with osteosarcoma have micrometastases at the time of diagnosis (Luu et al., 2021). The cancer has usually already seeded the lungs before the limp is investigated, whether or not anything shows on chest radiographs (Cohen & Hume, 2024).

This is why survival improves substantially when chemotherapy is added to amputation. Cornell reports a median of about four months with amputation alone and roughly nine months with chemotherapy added (Cohen & Hume, 2024). Luu et al. (2021) report somewhat wider ranges, at 101 to 177 days with surgery alone and roughly 247 to 366 days with adjuvant chemotherapy depending on the agent used. Taken together, expect something in the range of three to six months with amputation alone and roughly eight to twelve months with chemotherapy, with real variation between individual dogs.

Removing the leg removes the painful primary tumor. Chemotherapy targets what is already in the lungs. Even with multimodality therapy, metastasis to the lungs often occurs (Cohen & Hume, 2024).

For families facing this, it can help to know that a later lung metastasis is not evidence that the surgery failed or that something was missed. The disease was systemic from the start.

What Raises or Lowers the Risk

Across cancer types, a few factors recur:

• Surgical margins. Complete excision dramatically outperforms incomplete excision for both mast cell tumors and soft tissue sarcomas.
• Histologic grade. Higher grade means higher recurrence risk, most cleanly demonstrated in soft tissue sarcomas.
• Mitotic index. How fast tumor cells are dividing, often more predictive than grade for mast cell tumors.
• Tumor location. Muzzle mast cell tumors show 55% to 59% local lymph node metastasis compared with under 10% for other cutaneous sites (Garrett, 2014).
• Cancer type. The largest factor of all. Lymphoma and osteosarcoma behave fundamentally differently from a completely excised low-grade sarcoma.

What Monitoring Looks Like

Follow-up is not paranoia. It is how recurrence gets caught while options still exist.

Schedules vary by cancer and by patient. For osteosarcoma, rechecks every 2 to 3 months to monitor radiographs for metastasis may be recommended (Cohen & Hume, 2024). For high-grade soft tissue sarcomas, thoracic radiographs every 3 to 6 months long term are advised (Mullin, 2016).

Ask your oncologist for your dog's specific schedule and put it on a calendar. Between visits, contact your team about any new lump, a lump changing at a previous surgical site, enlarged lymph nodes, new lameness, coughing or exercise intolerance, appetite or weight loss, or any decline you cannot explain.

For dogs treated for lymphoma, owners are often taught to check lymph nodes at home, since increased lymph node size is how relapse is typically detected (North Carolina State University College of Veterinary Medicine, n.d.).

If It Does Come Back

Recurrence changes the plan. It does not automatically end it.

Depending on the situation, options may include a second surgery with wider margins, radiation for a site that cannot be re-excised, a rescue chemotherapy protocol, metronomic therapy using low-dose daily oral chemotherapy with an NSAID, or a shift toward palliative care focused on comfort.

On metronomic therapy specifically: it has been shown to significantly increase the time before recurrence in dogs with incompletely excised grade II soft tissue sarcomas (Mullin, 2016). That is the population it was studied in, so whether it applies to your dog's cancer is a question for your oncologist rather than an assumption to carry over.

That last option is a legitimate choice, not a surrender, and for many families it is the right one at a particular point.

Frequently Asked Questions

Does remission mean my dog is cured? No. Remission means the cancer is not currently detectable. Remission does not equal cure (North Carolina State University College of Veterinary Medicine, n.d.).

Can dog cancer ever be truly cured? Some can. Completely excised low-grade soft tissue sarcomas rarely recur (McSporran, 2009; Mullin, 2016), and the majority of mast cell tumors are cured with surgical excision (Garrett, 2014). Lymphoma and osteosarcoma are generally not curable with standard treatment.

How likely is lymphoma to come back? For multicentric lymphoma treated with CHOP, NC State cites approximately 95% of dogs relapsing (North Carolina State University College of Veterinary Medicine, n.d.). Indolent and small-cell lymphomas behave differently, so ask which type your dog has.

If the margins were clean, is my dog safe? Clean margins substantially improve the odds but do not guarantee anything, particularly with high-grade mast cell tumors, which in one analysis recurred 35.9% of the time despite clean margins (Garrett, 2014).

Does recurrence mean the first treatment failed? Not usually. In osteosarcoma, microscopic spread was already present at diagnosis in 90% to 95% of dogs (Luu et al., 2021). In lymphoma, relapse is an expected consequence of the disease rather than a sign that something went wrong.

The Bottom Line

Dog cancer can come back, and for lymphoma and osteosarcoma it usually does. For completely excised low-grade tumors, it often does not.

The three questions worth asking your oncologist are: what were my dog's margins, what was the grade and mitotic index, and what is our monitoring schedule. Those three answers will tell you far more about your dog's actual risk than any general statistic, including the ones in this article.

Recurrence is a chapter, not always the last one. Knowing it is possible lets you watch for it without living in fear of it.

This article is provided for educational purposes only and does not constitute veterinary medical advice, diagnosis, or treatment. Recurrence rates describe groups of dogs and cannot predict what will happen to an individual patient. Always follow the monitoring and treatment plan established by your veterinary oncology team.

References

Cohen, A., & Hume, K. (2024, August). Osteosarcoma in dogs. Cornell University College of Veterinary Medicine, Richard P. Riney Canine Health Center. https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-topics/osteosarcoma-dogs

Garrett, L. D. (2014). Canine mast cell tumors: Diagnosis, treatment, and prognosis. Veterinary Medicine: Research and Reports, 5, 49–58. https://doi.org/10.2147/VMRR.S41005

Luu, A. K., Wood, G. A., & Viloria-Petit, A. M. (2021). Recent advances in the discovery of biomarkers for canine osteosarcoma. Frontiers in Veterinary Science, 8, Article 734965. https://doi.org/10.3389/fvets.2021.734965

McSporran, K. D. (2009). Histologic grade predicts recurrence for marginally excised canine subcutaneous soft tissue sarcomas. Veterinary Pathology, 46(5), 928–933. https://doi.org/10.1354/vp.08-VP-0277-M-FL

Mullin, C. (2016, August 12; updated 2023, February 7). Canine soft tissue sarcomas. VETgirl. https://vetgirlontherun.com/canine-soft-tissue-sarcomas-vetgirl-veterinary-continuing-education-blogs/

North Carolina State University College of Veterinary Medicine. (n.d.). Medical oncology: Canine rescue lymphoma. NC State Veterinary Hospital. https://hospital.cvm.ncsu.edu/services/small-animals/cancer-oncology/oncology/canine-rescue-lymphoma/